This article outlines the epidemiology and role of nonsteroidal antiinflammatory drugs (NSAIDs) in causing gastrointestinal (GI) bleeding. The morbidity and mortality associated with NSAID-induced GI bleeding are discussed, and the…
Acute and chronic bleeding from the upper gastrointestinal tract is a common indication for endoscopy and hospitalization and is associated with significant morbidity and mortality. The causes of upper gastrointestinal…
Despite major advances in diagnosis, prevention, and treatment, nonvariceal upper gastrointestinal bleeding still is a serious problem in clinical practice. Current evidence indicates that most peptic ulcer bleeding–linked deaths are…
Upper gastrointestinal bleeding (UGIB) is an important medical problem for patients and the medical system. The causes of UGIB are varied and their accurate identification guides appropriate management. The major…
The gastrointestinal tract provides a unique window to access vascular structures in the mediastinum and abdomen. The advent of interventional endoscopic ultrasound (EUS) has enabled access to these structures with…
Intractable abdominal pain commonly develops in patients with pancreatic cancer. Oral pharmacologic therapy is ineffective for many patients and side effects commonly occur. Celiac neurolysis (CN) is sometimes performed to…
Surgery for pancreatic pseudocysts (PPCs) may be associated with high rates of complication and mortality. Since its introduction in the late 1980s, endoscopic drainage of PPCs has become established as…
Within the Patient Protection and Affordable Care Act of 2010 is a provision setting up a program for the implementation of accountable care organizations (ACOs). This article explains the proposed…
Patient registries have evolved to support goals within medical specialties that have traditionally fallen outside their core missions. Quality measurement and reporting can support payor advocacy, meet federal and state…
The medical device and pharmaceutical industry is facing mounting pressure to produce cost-effectiveness and clinical-effectiveness data in order for their products to be acceptable for approval by the Federal Drug…
